Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 12, 2016, Pages 2105-2113

  Schwarzenböck, Sarah M ^a,b   Eiber, Matthias ^a   Kundt, Günther ^b   Retz, Margitta ^a   Sakretz, Monique ^b   Kurth, Jens ^b   Treiber, Uwe ^a   Nawroth, Roman ^a   Rummeny, Ernst J ^a   Gschwend, Jürgen E ^a   Schwaiger, Markus ^a   Thalgott, Mark ^a   Krause, Bernd J ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Advanced prostate cancer; Choline; Docetaxel therapy; PET CT; Therapy response assessment

Indexed keywords

CHOLINE C 11; DOCETAXEL; ANTINEOPLASTIC AGENT; CARBON; CHOLINE; RADIOPHARMACEUTICAL AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE LESION; BONE METASTASIS; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CHOLINE UPTAKE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PET-CT SCANNER; PROSPECTIVE STUDY; RADIOCHEMISTRY; TREATMENT RESPONSE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; DRUG MONITORING; IMAGE ENHANCEMENT; MIDDLE AGED; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; CHOLINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAXOIDS; TREATMENT OUTCOME;

EID: 84975166466     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3439-9     Document Type: Article

References (24)

1. Siegel RL, Sahar L, Portier KM, Ward EM, Jemal A. Cancer death rates in US congressional districts. CA Cancer J Clin. 2015;65:339–44.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.
3. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14:2763–7.
4. Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, et al. External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer. BMC Urol. 2014;14:31.
5. Thalgott M, Rack B, Eiber M, Souvatzoglou M, Heck MM, Kronester C, et al. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients. BMC Cancer. 2015;15:458.
6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
7. Messiou C, Cook G, De Souza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer. 2009;101:1225–32.
8. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol. 1999;17:3461–7.
9. Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R, Borghesi M, et al. (11) C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging. 2016;43:84–91.
10. Mulders PF, Schalken JA. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2009;12:241–6.
11. Basu S, Kumar R, Ranade R. Assessment of treatment response using PET. PET Clin. 2015;10:9–26.
12. Maffione AM, Marzola MC, Capirci C, Colletti PM, Rubello D. Value of (18) F-FDG PET for predicting response to Neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. AJR Am J Roentgenol. 2015;204:1261–8.
13. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, et al. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13:113–23.
14. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, et al. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014;5:12448–58.
15. De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, et al. (18) F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42:1276–83.
16. Pascali C, Bogni A, Iwata R, Cambie M, Bombardieri E. [11C] methylation on a C18 Sep-Pak cartridge: a convenient way to produce [M-methyl-11C]choline. J Label Compd Radiopharm. 2000;43:195–203.
17. Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, et al. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. Am J Clin Pathol. 2010;134:964–9.
18. Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, et al. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy. J Cancer Res Clin Oncol. 2015;141:1457–64.
19. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for research and treatment of cancer (EORTC) PET study group. Eur J Cancer. 1999;35:1773–82.
20. Evangelista L, Bombardieri E. Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting? Eur J Nucl Med Mol Imaging. 2015
21. Caffo O, Maines F, Donner D, Veccia A, Chierichetti F, Galligioni E. Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2014;12:312–6.
22. Pezaro CJ, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270–3.
23. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F] fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29:623–9.
24. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148–59.